News

  • 4 November 2011

    Sequana Medical, the Medical University of Vienna and Vienna General Hospital (AKH Wien) reported that the first two commercial implants worldwide of the ALFApump System were performed at Vienna General Hospital in October, under the supervision of Univ. Prof. Dr. Markus Peck-Radosavljevic, Vice-Chairman, Division of Gastroenterology and Hepatology (Chairman: Prof. Dr. M. Trauner), Dept. of Internal Medicine III. Vienna General Hospital is one of Europe’s largest teaching hospitals. The ALFApump System is indicated for the management of refractory and recurrent ascites due to liver cirrhosis, a condition where massive and uncontrolled fluid accumulation occurs in the abdominal cavity.

  • 4 October 2011

    Creabilis SA, a clinical stage European biotechnology company addressing unmet medical needs in dermatology, inflammation and pain, has raised €15.0 million ($20 million) in a Series B funding round led by Abbott Biotech Ventures. Existing investors Neomed and Sofinnova Partners, as well as private Italian investors, joined the round. The new funds will be used to finance the development of the company’s first-in-class treatments, including its lead product CT327 to the end of phase II.

  • 30 September 2011

    JenaValve Technology GmbH, a German medical device company specializing in the development of transcatheter heart valve implantation systems, announced today that the Company has received CE mark approval for its second-generation transapical TAVI system. This system is used to treat severe aortic valve stenosis in elderly high-risk patients, especially in patients for whom conventional open-heart surgery is not an option.

  • 14 September 2011

    Endosense, a Swiss medical technology company focused on improving the efficacy, safety and accessibility of catheter ablation for the treatment of cardiac arrhythmias, has appointed Jan Keltjens as president and chief executive officer. Keltjens brings to Endosense more than two decades of leadership experience in the medical device and technology sectors. He has previously served as chief executive officer of AngioDynamics Inc. (NASDAQ: ANGO) and CryoCath Technologies Inc. (now Medtronic CryoCath) and held a number of senior leadership positions at Cordis Corp.

  • 3 August 2011

    Vessix Vascular, Inc. (formerly known as Minnow Medical, Inc.), a developer of novel percutaneous radiofrequency (RF) balloon catheter technology announced today that it has completed a $23 million Series B preferred stock financing. The lead investor in the financing round was Edmond de Rothschild Investment Partners (EdRIP) of Paris, France. Also participating in the financing was NY-based OrbiMed Advisors, CDF Dinova Venture Partners of Hong Kong along with existing investors NeoMed Management and Christopher Weil & Company.